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Abstract Cathepsin D is a lysosomal aspartic proteinase that 
has been implicated in several pathological processes such as 
breast cancer and Alzheimer's disease. We designed and 
synthesized a number of quenched fluorogenic substrates with 
P2 variations in the series AcEE(EDANS)KPIXFFRLGK(DA-
BCYL)E-NH2, where X = cysteine, methylcysteine, ethylcys-
teine, fert-butylcysteine, carboxymethylcysteine, methionine, 
valine or isoleucine. Most of the fluorogenic substrates exhibited 
greater kcatIKm ratios than the best cathepsin D substrates 
described so far. Differences in kinetic constants, which were 
rationalized using structure-based modeling, might make certain 
substrates useful for particular applications, such as active site 
titrations or initial velocity determination using a fluorescent 
plate reader. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cathepsm D (EC 3.4.23.5) is a highly abundant lysosomal 
aspartic proteinase widely distributed in various mammalian 
tissues. Inhibition studies along with amino acid sequence 
determinations of cathepsin D from different sources [1-4] 
indicated that the enzyme is a member of the pepsin family 
of aspartic proteinases. Due to its rather broad substrate spe-
cificity, cathepsin D is thought to play a major role in normal 
degradation of intracellular and extracellular endocytosed 
proteins [1]. In addition to normal physiological functions, 
cathepsin D has been associated with several biological proc-
esses of possible therapeutic significance. The enzyme seems to 
be involved in antigen processing and presentation of peptide 
fragments to class II MHC molecules [5-7]. Cathepsin D 
mediated proteolysis has also been linked to connective tissue 
diseases [8]. The enzyme can degrade extracellular matrix 
components [9] and may facilitate the spread of tumor cells 
via diverse mechanisms by its unregulated activity in the ex-
tracellular environment [10-12]. The observation of high levels 
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Abbreviations: EDANS, 5-(2-aminoethyl) aminonaphthalene-1-sul-
fonic acid; DABCYL, 4'-dimethylaminoazobenzene-4-carboxylic acid; 
D1C, diisopropyl carbodiimide; DMF, dimethylformamide; DMSO, 
dimethylsulfoxide; Fmoc, 9-fluorenylmethoxycarbonyl; HBTU, 2-
(lH-benzotriazol-1-yl) 1,1,3,3-tetramethyluronium hexafluorophos-
phate; HOBt, JV-hydroxybenzotriazole; NMP, JV-methyl-2-pyrrolli-
done; PAL, 5-(4-aminomethyl-3,5-dimethoxyphenoxy) pentanoic acid; 
TFA, trifluoroacetic acid 
of active cathepsin D within senile plaques in brains of Alz-
heimer's patients suggests that this enzyme may play a role in 
proteolytic cleavage of the amyloid precursor protein [13]. 
Recently, the major [3-amyloid precursor protein processing 
activity from Alzheimer's disease brain extracts was identified 
and found to be indistinguishable from the activity of cathep-
sin D [14,15]. 
To facilitate the search for specific inhibitors of cathepsin D 
and to facilitate studies of its enzymology, it is necessary to 
have a sensitive and continuous assay for enzyme activity. 
Since aspartic proteinases do not display esterase or amidase 
activities, which are most commonly exploited for proteinase 
assays, different approaches have been developed for contin-
uous monitoring of enzyme activity. In one technique, the 
substrate contains a chromophore, such as a nitrophenylala-
nine (F*) residue, in the PI ' position. Below pH 6.5, proto-
nation of the N-terminal F* generated during cleavage shifts 
its absorbance maximum from 278 to 272 nm, which makes it 
possible to continuously follow product formation by moni-
toring the absorbance decrease at 300-310 nm by UV spec-
troscopy [16-18]. 
A second method is based on the use of fluorogenic peptide 
substrates which contain fluorophor and quencher groups in 
the same molecule. The fluorescent signal in the uncleaved 
substrate is quenched due to resonance energy transfer be-
tween the fluorophor and quencher groups. The increase in 
fluorescence during substrate cleavage can be continuously 
monitored using fluorescence spectroscopy [19]. The use of 
EDANS1 (5-[(2-aminoethyl)amino]naphthalene-1 -sulfonic 
acid) and DABCYL (4-(4-dimethylaminophenylazo) benzoic 
acid) as respective fluorophor and quencher was initially 
shown to provide good fluorogenic substrates for HIV-1 and 
AMV proteinases [20]. Fluorogenic substrates for aspartic 
proteinases with o-aminobenzoic acid and p-nitroanilide as 
the fluorophor and quencher pair were recently described by 
Filippova et al. [21]. 
In this report, we describe the design, synthesis and cata-
lytic properties of a series of fluorogenic substrates for human 
cathepsin D. Different residues in the P2 position were exam-
ined and their effects on substrate binding were rationalized 
using the crystal structure of human cathepsin D [22]. 
2. Materials and methods 
Cathepsin D was purified from human liver as described [23], 
lyophilized and stored at —70°C prior to use. Glycine, sodium acetate, 
hydrochloric acid and pepstatin A were purchased from Sigma Chem-
ical Co., dimethylsulfoxide (DMSO) and Triton X-100 were pur-
chased from Aldrich Chemical Co., Inc. 
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2.1. Modeling 
Modeling and energy minimizations were performed with Biosym's 
Insightll/Discover software on a Silicon Graphics workstation. Pa-
rameters and charges for the diazo bond in DABCYL were obtained 
from Density Functional calculations performed with DGauss on a 
Cray-YMP as implemented in the Unichem software package (Cray 
Research). The substrates were modeled in the binding site of cathep-
sin D in several steps. In the first step, the peptide K-P-I-C-F-F-R-L-
G was superimposed onto the P1-P3 sites of pepstatin A using the 
crystal structure of the cathepsin D/pepstatin A complex [22]. After 
making the appropriate side chain modifications, the peptide was en-
ergy minimized in the binding site, and the P l ' -P3 ' residues were then 
manipulated manually to optimize the van der Waals packing and 
polar interactions. A water molecule was then modeled to fit between 
the two catalytic aspartates and the scissile bond of the peptide. Fi-
nally, the rest of the substrate was modeled and the EDANS and 
DABCYL groups were added. The added residues were then manually 
optimized to remove steric contacts. Energy minimizations were per-
formed after each step in the procedure. 
2.2. Synthesis 
The Na-Fmoc-Ne-DABCYL-L-lysine and N-Fmoc-L-glutamic acid-
y-EDANS were prepared using the modified procedure of [24]. All 
substrates were synthesized by the solid phase method using the 
Fmoc group for a-amino protection and acid labile groups for side 
chain protection of trifunctional amino acids. Aminomethyl polysty-
rene resin modified with PAL linker to a substitution of 0.3-0.4 mmol/ 
g was used as the solid support. The FmocLys(DABCYL)OH and 
FmocGlu(EDANS)OH were coupled overnight in DMF as HOBT 
esters (DIC activation) using 3-fold molar excess of amino acid. All 
other steps were performed on a peptide synthesizer (Applied Biosys-
tems, Model 430A) using a 10-fold molar excess of amino acid, 
HBTU and HOBt as coupling reagents, and NMP as solvent. The 
final cleavage of substrates from resin was accomplished by treatment 
with a mixture of TFA, thioanisole, ethanedithiol, and anisole 
(90:5:3:2). The crude substrates were purified by reverse phase 
HPLC on a VYDAC C18 column (25x2.5 cm) using 0.05% aq. 
TFA-acetonitrile mixtures in a gradient elution. Purity of all com-
pounds was checked by analytical HPLC (column VYDAC C18, 
25X0.4 cm) in 0.05% aq. TFA-methanol mixtures. All compounds 
gave correct amino acid analysis and correct molecular peaks using 
ion spray MS. Substrates were dissolved in 100% DMSO prior to use. 
2.3. Kinetics 
The increase of fluorescence during substrate cleavage was moni-
tored using an Aminco Bowman-2 luminescence spectrometer (SLM 
Instruments, Inc.). Typically, 489 ill of 50 mM Gly-HCl buffer, pH 3.5, 
was mixed with 5 |il of DMSO and 1 ul of cathepsin D (0.14-
0.3 pmol). The mixture was pre-incubated for 4 min at 37°C and 
reaction was initiated by the addition of 5 ul °f substrate in 
DMSO. The final substrate concentration range was 1-20 uM; Anal 
DMSO concentration was 2% for all assays. Increase in fluorescence 
intensity at the emission maximum of 487 nm with excitation at 349 
nm was recorded as a function of time. The initial velocity, measured 
as fluorescence intensity per unit time (Vf), was calculated from the 
slope during the linear phase of cleavage, usually 50-100 s, by a first 
degree polynomial fit using the SLM AB2 2.0 operating software. The 
inner filter effect [25] was negligible in the range of substrate concen-
tration used, as measured by the linearity of fluorescence increase with 
substrate concentration after complete hydrolysis. Initial velocities 
were converted from units of fluorescence (V() to concentration per 
unit time (Vc) using the equation: 
Vc = Ff*[S]/(F,oo-Fo) 
where [S] is substrate concentration, and FQ and Fioo are the fluores-
cence intensities of substrate solution before and after complete hy-
drolysis. Initial velocity data were fitted to the Michaelis-Menten 
equation using the program Enzfitter to calculate Fmax and Km values. 
Enzyme active site concentrations used for the &cat calculations were 
determined by titration of cathepsin D using the tight-binding inhib-
itor pepstatin A. 
The cathepsin D stock solution used for the kinetic experiments 
contained 0.05% Triton X-100 such that the final concentration of 
detergent in the reaction mixture was 0.0001%. Under these condi-
tions, no change of Cathepsin D activity in the enzyme stock solution 
was detected during the total length of the experiment (up to 3 h at 
0°C). In the absence of Triton X-100, we observed up to 50% enzyme 
inactivation over the same period of time. This inactivation is most 
likely a result of non-specific surface adsorption of cathepsin D rather 
than a result of autolysis since no significant change in enzyme activ-
ity was detected after 100 min incubation of 14 |iM cathepsin D over 
a broad pH range (3.0-7.0) at 37°C (S.V.G., unpublished results). 
2.4. HPLC separation of cleavage products 
To confirm the P l - P l ' cleavage site, 2.5 ml of 10 uM substrate 5 
(Table 1) solution in 0.1 M sodium acetate buffer, pH 3.3, containing 
1% DMSO and 4 nM cathepsin D was incubated overnight at room 
temperature. Two product peptides were separated on a u-Bondapak 
C18 3.9x300 mm reverse phase column using a 60 min linear 0-60% 
gradient of acetonitrile in 0.05% TFA. Cleavage products were sub-
jected to both amino acid and sequence analysis. As expected, cathep-
sin D cleaved the substrate between the two phenylalanine residues. 
Cathepsin D cleavage of substrates 6, 8, 10 similarly yielded only two 
products that could be detected by HPLC. In each case, the elution 
time of one of the products was identical to that of the 
(FRLGK(DABCYL)E-NH2) product from substrate 5, confirming 
the existence of a single cleavage site between the two phenylalanine 
residues. 
3. Results and discussion 
In this study, we evaluated a series of novel, intramolecu-
larly quenched fluorogenic substrates for human cathepsin D. 
The peptide part of the substrates was derived from the se-
quence K-P-I-L-F-F*-R-L as described for a cathepsin D sub-
Table 1 
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Fig. 1. The model of side chains of cysteine (5) and methylcysteine (6) in S2 pocket of cathepsin D. 
strates by Scarborough, et al. [18]. Several charged amino 
acids were added to the N- and C-termini of the peptide to 
attach fluorophor and quencher molecules and to increase 
solubility of the substrate. The F* residue at P I ' was replaced 
by the natural phenylalanine residue since the nitro group 
is not necessary for substrate turnover. EDANS and 
DABCYL were chosen as the fluorophor and quencher 
groups, respectively. This donor-acceptor pair is character-
ized by a number of advantages such as extremely good spec-
tral overlap of EDANS emission with the strong absorption 
band of DABCYL and good quantum yield, stability against 
photobleaching, and Stokes shift of over 100 nm for EDANS 
[20]. 
Kinetic parameters for cleavage of various fluorogenic sub-
strates are presented in Table 1. Introduction of the fluoro-
phor and quencher groups into substrates with the same PS-
PS' core sequence as the F-F* substrates resulted in a 5-6 fold 
decrease in Km value (compare 1 and 3, and 2 and 4). The 
added binding potency may be due to the increased length of 
the fluorogenic substrates (P7-P6') or to the presence of the 
bulky DABCYL and EDANS groups. The kc&t values for the 
chromogenic and fluorogenic substrates were similar, how-
ever, suggesting that the donor-acceptor groups at distal po-
sitions did not significantly influence peptide catalysis. The 
ratio of Km values for the substrates with Val and Leu in 
P2 (4 and 3) is 1.3, which is also in good agreement with 
the data of Scarborough et al. (1993). Introduction of sul-
fur-containing side chains in P2, such as Cys (5), modified 
cysteines (6, 8, 9) and Met (10) slightly improved binding, 
with the exception of ethylcysteine (7). Modeling analysis in-
dicated that the side chains of Cys and methylcysteine fit 
nicely into the hydrophobic S2 pocket of cathepsin D, making 
favorable hydrophobic interactions with the side chains of 
Met307, Met309, Val238 and He320 (Fig. 1). 
Interestingly, there is nearly a 10 fold difference in Km be-
tween substrates 7 and 10. Yet, the side chains of Met and 
ethylcysteine contain the same number of atoms, and differ 
only by the position of the sulfur atom in the chain. Modeling 
analysis revealed a substantial geometric difference that would 
result from location of sulfur atom in the side chain (Fig. 2). 
The C-S-C bond angle, which is close to 90 deg, is located 
further from the substrate backbone in the Met side chain, 
and it allows it to adopt a favorable compact conformation in 
the S2 pocket. In the case of ethylcysteine, the sulfur atom is 
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Fig. 2. Different conformation of Met (10) and ethylcysteine (7) in S2 
too close to the backbone to allow for an optimal compact 
conformation. We were unable to find a good fit for ethyl-
cysteine without bumping either into itself or to the side 
chains forming the S2 subsite and conclude that substrate 7 
has to alter its backbone conformation in order to fit into the 
S2 pocket of cathepsin D. The resulting strain introduced into 
the scissile amide bond might lower the activation energy of 
cleavage, since the initial bound intermediate would be less 
stable, and may explain the unusually high kCBX value observed 
for this substrate (196 s_1) which is the highest value ever 
described for a cathepsin D substrate. 
The P2 side chain of carboxymethylcysteine (9) makes a 
unique set of interactions in the S2 pocket with its carboxy 
group at the position to form hydrogen bonds with the amide 
NH groups of Ser235 and Leu236 and the OH group of Ser235 
(Fig. 3). This carboxy group is also partially exposed to sol-
vent and therefore should contribute to the solvation energy 
of binding. These reasons may make the interactions in S2 
quite favorable and explain the low Km of 3.9 |xM for 9. On 
the other hand, the favorable hydrogen bonds made by the 
carboxymethyl group with the enzyme backbone may interfere 
subsite depends on the position of the sulfur atom of the side chain 
with product release and account for the low kcat for this 
substrate. 
Most of the fluorogenic substrates described here have 
greater kcsAIKm ratios than the best cathepsin D substrates 
described so far [18,21]. They have low Km values and a rather 
wide range of kca,t values (5.8-196 s
_1) which makes them 
suitable for different kinetics applications. For example, the 
substrate with X = ethylcysteine (Km = 27.5 uM, kcat = 196 s
_1) 
might be convenient for active site titrations since it permits 
the use of substrate concentrations far below the Km. The 
substrate with X = carboxymethylcysteine which has a low 
Km with a slow kcaX (Km = 3.9 |xM, kclA = 5.8 s
_1) could be 
used in an assay format that requires the reaction velocity 
to remain constant during a prolonged period, such as the 
cycling time of a fluorescent plate reader. Moreover, the in-
crease in assay sensitivity afforded by these substrates allowed 
us to decrease the enzyme concentration used for the assay 
from 1-6 nM [18] to 0.2-0.3 nM. For routine screening of 
inhibitors, it is possible to use as low as 0.05-0.1 nM of 
cathepsin D which permits more precise determination of sub-
nanomolar Ki's. 
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Fig. 3. Hydrogen bonds made by partially solvent exposed carboxyl group of carboxymethylcysteine may stabilize Michaelis complex and inter-
fere with product release. 
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